total revenu y/i fx well ahead
estim organ growth vs estimate
beat broad-bas end-market product categori led analyt
instrument ai core gross opmargin declin
yoy expect due pthn deal opm in-lin w/ est adj ep
street beat larg expect better even
bullish expect underscor tmo strong fundament first look
page note detail end-market geographi guidanc
one thermo rule growth acceler
rais organ sale guid adj ep
mdpt vs prior said view updat guid larg
captur beat oper improv built rest
year still somewhat conserv given tmo key end-market appear
boom unison market environ strength tmo diversifi
global busi amplifi believ share well-posit
narrow pe valuat gap lst peer also emphas throughout
call win share vs competit sever key market notabl
chromatographi mass spectrometri bode well continu improv
organ growth profil reiter buy rate share see
divers underappreci strength look forward updat
healthcar confer may tmo annual analyst day may
rais estim see organ
estimate sale y/i organ fx vs
prior adj ep y/i sale
organ yoy vs prior adj ep
yoy vs prior po dcf base w/ wacc due higher impli
market return termin growth rate improv metric unchang
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
life scienc solut sale segment sale
y/i organ fx flat vs estim y/i
organ fx segment benefit strong growth across
segment particularli bioproduct next-gener sequenc
bioscienc busi opm yoy strong
product volum pull-through foreign exchang partial off-set
strateg invest unfavor busi mix
analyt instrument sale analyt instrument revenu
y/i organ fx vs
strength busi across segment fei/electron microscopi
chromatographi mass spec chemic analysi opm
strong product volum pull-through off-set strateg invest
specialti diagnost sale specialti diagnost revenu
y/i organ fx vs estim
y/i organ fx management report strong growth
health care market channel flu tailwind although mostli off-set weak
allergi season opm yoy product gain
off-set product mix flu lower margin allergi strateg
laboratori product servic lp sale laboratori product
servic lp revenu y/i organ fx
 vs estim y/i organ fx
 management note particularli good growth channel catalog busi
clinic trail busi neg affect
discontinu larg phase clinic trial late opm
yoy favor volum pull-through off-set strateg
invest unfavor product mix
academ govern revenu grew mid-singl digit y/i
modest growth north america good strength europe/china
diagnost healthcar sale grew low-singl digit consist
recent trend flu tailwind larg off-set weak allergi quarter
neg affect margin
industri appli growth end-market high-singl digit
led broad strength apac reason market condit
pharma sale grew yoy management note particular
strength across end-market bioproduct chromatographi mass spec
channel busi well share gain chromatographi mass
spec like compet
north america sale lsd
europ sale msd
asia pacif sale mid-teen includ anoth quarter high-teen
growth china sale
rest world sale msd
revenu rais sale guid
mdpt midpoint equat report growth vs prior
yoy report expect
organ growth guid rais vs prior
year
increment acquisit stronger patheon perform
plu impact integenx small tuck-in
increment higher fx tailwind total
bit conserv given volatil rate
margin expect oper margin expans y/i
inclus margin dilut pthn acquisit
interest expens manag expect full year net interest expens
result pthn acquisit assum quarterli fed rate hike
unchang
tax rate manag expect adjust tax rate
level result recent pass us tax reform unchang
capit deploy share buyback complet
second half also plan total dividend payment
year usual compani note capit deploy
embed current guidanc excess cash use repay debt
share count manag estim averag dilut share
vs due equiti offer financ pthn deal
unchang
capit expenditur manag expect net capit expenditur
approxim elev due time project
full-year impact patheon receiv approxim custom
fund toward capital-expenditure free cash flow expect
ep non-gaap ep rais prior
oper perform increment fx
total fx integenx dilut
po base dcf model assum wacc termin
growth rate impli multipl approxim ep estim given
size market leadership matur stabil compani consum
focus busi believ dcf appropri way valu
compani risk price object deal integr risk lower-than-expect
deal synergi slower growth emerg market price eros lower healthcar
util trend soft uptak new product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
